Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Author:

Robert Caroline,Thomas Luc,Bondarenko Igor,O'Day Steven,Weber Jeffrey,Garbe Claus,Lebbe Celeste,Baurain Jean-François,Testori Alessandro,Grob Jean-Jacques,Davidson Neville,Richards Jon,Maio Michele,Hauschild Axel,Miller Wilson H.,Gascon Pere,Lotem Michal,Harmankaya Kaan,Ibrahim Ramy,Francis Stephen,Chen Tai-Tsang,Humphrey Rachel,Hoos Axel,Wolchok Jedd D.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Cited by 3786 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Peptide nanovaccine in melanoma immunotherapy;International Immunopharmacology;2024-03

2. Bio-markers of immuno-oncology;Journal of Pharmaceutical and Biological Sciences;2024-02-15

3. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events;Frontiers in Immunology;2024-02-05

4. Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma;Expert Review of Molecular Diagnostics;2024-02-05

5. Incorporating Real Option Value in Valuing Innovation: A Way Forward;PharmacoEconomics;2024-02-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3